Related
Epigenetic markers of Melanoma Prognosis
TRL: 4
Availability: Licensing
Status: EP Patent
Immunogenic synthetic glycoconjugate for the immunotherapy of melanoma
TRL: 4
Availability: other
Status: US Patent